6月25日 - ** 药物开发商Viking Therapeutics VKTX.O股价盘前上涨1.1%至27.25美元
** VKTX表示， (link)，它已开始对其实验性GLP-1肥胖症候选药物VK2735进行口服和注射剂型的后期研究。
** 该公司表示，这项后期研究将在78周的时间里对成人肥胖症患者和超重或肥胖的成人2型糖尿病患者进行测试。
** 截至上一交易日收盘，VKTX 股价累计下跌 33
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.